You are here: Home > MDL > Mirapex > Introduction

Introduction

Description of MDL No. 07-1836 (JMR/FLN)

In re Mirapex Product Liability Litigation

This multidistrict litigation consists of over 250 cases in each of which the plaintiff claims to have been damaged by a drug called Mirapex, a prescription medication commonly used to treat Parkinson's Disease and Restless Leg Syndrome. Plaintiffs have been prescribed Mirapex. Plaintiffs allege that Mirapex causes pathological gambling and other compulsive behaviors. They claim that Defendants failed to timely disclose these alleged side effects.

Defendants Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer, Inc., Pharmacia Corporation, Pharmacia & Upjohn Company developed, manufacture and market Mirapex. Defendants contend that Plaintiffs' claims lack merit, and that Plaintiffs will be unable to prove that Mirapex caused any of their damages.

The Judicial Panel on Multidistrict Litigation determined that the Mirapex cases involved common questions of fact, and that centralization of the cases in Minnesota was appropriate. All Mirapex cases were transferred to the District of Minnesota for coordinated or consolidated pretrial proceedings. The cases are assigned to Judge James M. Rosenbaum and Magistrate Judge Franklin L. Noel. Any subsequent Mirapex case filed in federal court will be transferred to the District of Minnesota and become part of MDL No. 07-1836 as a "tag along" case.